EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSJJAG00000016736
Gene Symbol: MAP2K2
2 Cross references
260 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSJJAG00000013490
Gene Symbol: MAP3K1
3 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSJJAG00000011801
Gene Symbol: MAP3K11
3 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSJJAG00000007805
Gene Symbol: MAP3K12
3 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSJJAG00000021115
Gene Symbol: MAP3K13
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSJJAG00000010969
Gene Symbol: MAP3K8
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSJJAG00000004772
Gene Symbol: MAP3K9
3 Cross references
194 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSJJAG00000011331
Gene Symbol: MAOA
3 Cross references
147 Possible Orthologues:

Monoamine Oxidase B

Ensembl ID : ENSJJAG00000012262
Gene Symbol: MAOB
3 Cross references
329 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSJJAG00000017428
Gene Symbol: MGLL
3 Cross references
208 Possible Orthologues:

Multidrug Resistance Protein 2-Like

Ensembl ID : ENSJJAG00000016731
Gene Symbol: LOC101595257
2 Cross references
148 Possible Orthologues:

Myeloperoxidase

Ensembl ID : ENSJJAG00000020363
Gene Symbol: MPO
3 Cross references
181 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).